Are Black patients with high-risk NSTE ACS less likely to receive evidence-based treatments compared to White patients?
There are significant racial disparities in the management of high-risk NSTE ACS, with Black patients being less likely to receive newer or costly evidence-based treatments.
Black patients with NSTE ACS were less likely than whites to receive many evidence-based treatments, particularly those that are costly or newer. Longitudinal studies are needed to assess the long-term impact of these treatment disparities on clinical outcomes.
Sonel et al. (2005) studied this question.